Abstract

Bosentan 6.25-mg/mL Oral Suspension

Author(s): Allen Loyd V Jr

Issue: Nov/Dec 2016 - Volume 20, Number 6

Page(s): 505

Download in electronic PDF format for $75

Abstract

A formulation for preparing Bosentan 6.25-mg/mL Oral Suspension. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Nov/Dec 2016 Pg. 505	Bosentan 6.25-mg/mL Oral Suspension Author(s): Allen Loyd V Jr
Mar/Apr 2003 Pg. 106-113	Veterinary Transdermal Medications: A to Z Author(s): Davidson Gigi S
May/Jun 2004 Pg. 181-185	Compounding in the Pharmacy Curriculum: Beyond the Basics Author(s): Hinkle Amanda R, Newton Gail D
Nov/Dec 2004 Pg. 462-465	Basics of Compounding for Cough Author(s): Allen Loyd V Jr
Jan/Feb 2013 Pg. 24-27	Treatment of Canine Pulmonary Hypertension: Is Tadalafil an Appropriate Alternative to Sildenafil? Author(s): Wung Deanna
Jan/Feb 2010 Pg. 40-45	Diverse Challenges in Pediatric Compounding: Treating Pulmonary Hypertension, Uncombable Hair Syndrome, and Acanthamoeba keratitis Author(s): Muller George, Young Thomas W, Reina Rachel, Caldwell Delmar R
Nov/Dec 2006 Pg. 405-408	Application of Sildenafil for Pulmonary Hypertension in Canines and Foals Author(s): Davidson Gigi S
Mar/Apr 2016 Pg. 145	Carvedilol 3.125-mg, 6.25-mg, 12.5 mg, or 25-mg capsules Author(s): Allen Loyd V Jr
May/Jun 2002 Pg. 203	Ergoloid Mesylates 15-mg/mL and Selegiline HCl 6.25-mg/mL in PLO Author(s): Allen Loyd V Jr
Jan/Feb 2012 Pg. 34-41	Compounded Pimobendan for Canine Chronic Degenerative Mitral Valve Disease and Pulmonary Hypertension Author(s): Helms Scott R, Fox Samantha, Mixon William, Vail Jane
Jul/Aug 2002 Pg. 286-287	Medications Discontinued in the United States Author(s): Ashworth Lisa D
Jan/Feb 2021 Pg. 43	Amlodipine Besylate 0.5-mg/mL to 10-mg/mL in SuspendIt Oral Suspension Author(s): Allen Loyd V Jr
Jan/Feb 2021 Pg. 44	Clonidine 0.01-mg/mL in Oral Mix and Oral Mix SF Suspension Author(s): Allen Loyd V Jr
Sep/Oct 2023 Pg. 420	Nitazoxanide 20-mg/mL Oral Suspension Author(s): Allen Loyd V Jr
May/Jun 2018 Pg. 263	Erratum: Formulation: Lansoprazole 3-mg/mL Oral Suspension Author(s):
Jan/Feb 2021 Pg. 47	Metronidazole 50-mg/mL in Oral Mix and Oral Mix SF Suspension Author(s): Allen Loyd V Jr
Sep/Oct 2021 Pg. 415	Dapsone 2-mg/mL in Oral Mix or Oral Mix SF Suspension Author(s): Allen Loyd V Jr
Sep/Oct 2021 Pg. 416	Dexamethasone 1-mg/mL in Oral Mix or Oral Mix SF Suspension Author(s): Allen Loyd V Jr
Nov/Dec 2021 Pg. 503	Metoprolol Tartrate 10 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Nov/Dec 2021 Pg. 505	Pyridoxine Hydrochloride 25 mg/mL in Oral Mix and Oral Mix SF Suspension Author(s): Allen Loyd V Jr